In “Immunotherapy in MSI-High and dMMR mCRC,” Dr. Strickler discusses how immune checkpoint inhibition has reshaped treatment ...
Real-world evidence indicates that longer biologic dosing intervals are associated with higher persistence and fewer ...
Dr. Haumschild compares SGLT2 inhibitors and GLP-1 receptor agonists as evidence in both classes keeps evolving. He acknowledges GLP-1s carry real budget impact that payers cannot ...
Karolinska Institutet’s Antoine Créon, MD, explains how alert fatigue, workflow, and center-level variation may have limited ...
Permanent standard time is the only option that ends biannual clock changes while keeping the body aligned with the sun, ...
Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a ...
Not every patient who carries Clostridioides difficile ( C diff) gets sick, and distinguishing colonization from true ...
Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling ...
OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear ...
The FDA on Friday approved a subcutaneous (SC) induction regimen for risankizumab-rzaa (Skyrizi; AbbVie) in adults with ...
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 ...
Universal HCV testing, community-based prevention, and peer navigators can help curb a decade-long surge in new US hepatitis ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results